IL25 and colon adenocarcinoma: Furthermore, IL-25-signalling blockade via anti-IL17BR antibody administration in Apc1322T/+ mice reduced ILC2s and pro-tumoral MDSCs while increasing IFNγ+ CD4+ and CD8+ T cells in colonic adenocarcinomas, indicating a potential therapeutic intervention to block the pro-tumoral role of the IL-25-ILC2-monocytic MDSC (M-MDSC) axis in CRC.